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Introduction
Chronic kidney disease (CKD) is a frequent complication in glycogen storage disease type I (GSDI) and can progress to renal failure. GSDI is a rare metabolic disease caused by deficient glucose-6 phosphatase (G6Pase) activity, resulting in the decrease in endogenous glucose production (1, 2) . G6Pase catalytic subunit (G6PC) deficiency results in GSD type Ia and glucose-6 phosphate translocase deficiency results in GSD type Ib (3) (4) (5) . Patients with GSDIa or GSDIb present a wide spectrum of clinical manifestations, including fasting hypoglycemia, hypertriglyceridemia, hypercholesterolemia, hyperuricemia and lactic acidosis. Excessive accumulation of glycogen and fat in the liver and kidneys leads to chronic hepatic and renal complications (6) (7) (8) . Patients with GSDIb also suffer from neutropenia associated with recurrent bacterial infections (6, 7) . The view on renal complications in GSDI is merely based on the collaborative European Study on GSDI (ESGSDI) cohort, which retrospectively included 231 GSDIa and 57 GSDIb patients. Thus, renal manifestations of GSDI appear in early childhood (8, 9) . Almost 70% of young adult patients exhibit hyperfiltration and microalbuminuria, and 40% develop proteinuria (8, 9) . Many patients also have nephrocalcinosis, due to hypercalciuria and hypocitraturia that enhance the likelihood of urinary calcium precipitation. As with diabetic nephropathy, this dysfunction remains clinically silent for a long time (6, 10, 11) . Unfortunately, few data are available on the evolution of this CKD over time, because of the small number of patients and a lack of longitudinal clinical data.
To characterize the evolution of kidney dysfunctions in GSDIa, we generated a viable mouse model in which G6PC deletion was restricted to the kidneys (K.G6pc -/-mice). Interestingly, K.G6pc -/-mice developed early-onset nephropathy, including nephromegaly and microalbuminuria after 6 months of G6pc deletion (12) . However, long-term renal complications, such as interstitial fibrosis and focal segmental glomerulosclerosis observed in GSDI patients (6), were not observed in mice at this stage (12) . In this study, we show that the development of renal interstitial fibrosis and glomerular sclerosis induced by longterm G6pc deletion results in the later development of polycystic kidneys, and then to the development of renal failure in the final stage of the disease. On the basis of our findings in mice, we were able to detect the development of cysts in 22% of GSDI patients (6 patients with GSDIa and 1 patient with GSDIb) in a cohort of 32 individuals. Strikingly, renal cysts were never reported in individuals with GSDI.
Results

Deterioration in tubule function in K.G6pc -/-mice
To characterize the development of nephropathy in GSDIa, we studied the natural course of deterioration of the renal function in K.G6pc -/-mice for 18 months. In contrast to total G6pc knockout mice (3), K.G6pc -/-mice showed no growth retardation and had similar weight gain and glycaemia to control (WT) mice. However, K.G6pc -/-mice exhibited gradual weight loss after 14 months of G6pc deletion (Supplementary Material, Fig. S1 ). As previously observed, K.G6pc -/-mice exhibited enlarged and paler kidneys compared to WT kidneys ( Figure 1 ) . Kidney enlargement increased with age ( Figure 1A and B) and the kidney weight of K.G6pc -/-mice was about 2.5-fold higher than that of WT mice at 18 months ( Figure 1C ). As expected, we observed an accumulation of excessive glycogen in the proximal tubule cells in K.G6pc -/-kidneys ( Figure 2A ). As we had previously observed deposits of lipids in the K.G6pc -/-kidneys (12), we quantified the renal lipid content. The content in triglycerides reached 9.0 6 1. 2 mg/g of tissue compared to 3.5 6 0.7 mg/g of tissue in WT mice after 9 months of G6pc deletion. However, no further increase in triglyceride accumulation was observed between 9 and 18 months ( Figure 2B ). Histological observations revealed large lipid droplets in the tubule cells in K.G6pc -/-kidneys at 9 months ( Figure 2C ). Thus, both the accumulation of lipids and excessive glycogen in the proximal tubules led to the clarification and enlargement of tubular cells ( Figure 3A) . Renal tubules play an important role in urine formation, and fluid electrolyte and acid-base homeostasis. Consequently, tubular damage appeared early since K.G6pc -/-mice presented polyuria, urinary acidification and electrolyte imbalance at this stage (12) . However, polyuria gradually worsened with age (Table 1) , concomitantly with polydipsia (Supplementary Material, Fig. S2 ), confirming an inability to concentrate urine. Thus, urine production was about 4-fold higher that of WT mice at 18 months (Table 1) . As previously observed at 6 months, the urinary pH of K.G6pc -/-mice was also more acidic than that of WT mice at each stage (Table 1 ). In addition, the excretion of urea and uric acid increased with age (Table 1 ). In parallel, biochemical analyses also revealed normal plasma uric acid, cholesterol and triglyceride levels, indicating normal liver metabolism in K.G6pc -/-mice ( Table 2 ).
Contrary to most GSDIa patients, no nephrolithiasis was observed in K.G6pc -/-mice despite hypercalciuria. This can be explained by the fact that hypocitraturia was not observed concomitantly with a hypercalciuria. On the contrary, K.G6pc -/-mice developed hypercitraturia and hypercalciuria (Supplementary Material, Table S1 ). We previously suggested that this could protect mice from calcium stone development (12) . In addition, K þ concentration was increased in the urine of Table S1 ). No modification in chloride, magnesium, phosphate, sodium and oxalate excretion was observed in K.G6pc -/-mice (Supplementary Material, Table S1 ).
In conclusion, these data show that tubular damage is an early hallmark of K.G6pc -/-kidneys, and suggest that these defects are probably secondary to the accumulation of glycogen and lipids.
Development of filtration barrier damage and renal failure in K.G6pc -/-mice with age
Our previous study showed that the first signs of impairment of the filtration barrier (i.e. microalbuminuria) occurred after 6 months of G6pc deletion (12) . However, electron microscopy images and histological analyses of K.G6pc -/-kidneys showed intact glomerular structures and no fibrosis at this age (12) . Comparable alterations in biochemical urine and plasma parameters were observed at 9 months (Tables 1 and 2) . Nevertheless, albuminuria increased considerably in K.G6pc
-/-mice at 15 and 18 months, reaching 776 6 264 mg/24h in K.G6pc -/-mice compared to 97 6 18 mg/24h in WT mice at 18 months (Table 1) . Interestingly, the accumulation of blood urea nitrogen (BUN) was observed after only 15 months of G6pc deletion (but not after 12 months, data not shown) ( Table 2) . These results suggest the onset of renal failure, potentially responsible for the weight loss observed at this age (Supplementary Material, Fig. S1) . Interestingly, the level of Lipocalin 2 (LCN2), recently considered as a promising biomarker of CKD progression (13, 14) , progressively increased in urine in K.G6pc
-/-mice ( Table 1 ) and was significantly higher in the plasma in the renal failure stage (Table 2 ). This was associated with a marked increase in Lcn2 mRNA expression in K.G6pc -/-kidneys observed after only 9 months of G6pc deletion (Supplementary Material, Fig. S3 ), confirming that the kidney is the major source of urinary LCN2 (13, 15) . These results suggest a gradual degradation of the filtration barrier with aging in K.G6pc -/-mice, leading to a late-onset of renal failure after 15 months of G6pc deletion.
Progressive tubular and glomerular fibrosis and development of renal cysts in K.G6pc -/-mice with age
As the process of excessive fibrosis is a major cause of CKDs, we analyzed the progression of fibrosis in K.G6pc -/-kidneys. It is noteworthy that the kidneys were macroscopically sclerotic after 15 months of G6pc deletion and cystic after 18 months ( Figure 1A ). As observed after 6 months, neither renal fibrosis nor glomerular injury were observed after 9 months of G6pc deletion ( Figures 3 and 4 , Supplementary Material, Fig. S4 ). After 15 months, early cell degeneration and necrosis were observed in tubules with condensed nuclei. In addition, inflammatory (lymphoid and plasma cells) areas and fibrosis were observed in the interstitium of the cortex ( Figure 3A and B). At 18 months, tubular dilation, inflammation and fibrosis were more significant and numerous microscopic and macroscopic cysts up to 3-4 mm were observed (Figure 3 ). This was consistent with the progressive increase in mRNA expression of the proinflammatory cytokine TNF-a ( Figure 3C ). In addition to large areas of interstitial fibrosis, glomerular scarring was observed ( Figure  3B ). As observed in diabetes, the glomeruli showed mesangial hypertrophy and expansion at 15 and 18 months, leading to an increase of glomerular size (Supplementary Material, Fig. S4 ).
No tubular dysplasia or preneoplastic lesion was observed in K. G6pc -/-kidneys. In agreement with histological observations, the thickness of the glomerular basement membrane was more prominent in K.G6pc -/-mice after 15 and 18 months compared to WT mice ( Figure 4A and B). In addition, foot process effacement was observed at both ages ( Figure 4A ) and confirmed the substantial podocyte injury. Furthermore, Western Blot analyses showed that the amount of structural proteins of the filtration barrier (podocin and nephrin) had already slightly decreased at 9 months and was markedly reduced at 18 months ( Figure 4C ). Thus, these results show that the development of interstitial and glomerular fibrosis results in the later development of polycystic kidneys in GSDIa mice. This is associated with a marked destruction of the filtration barrier that finally leads to renal failure.
Molecular mechanisms involved in renal fibrosis in K.G6pc -/-mice
One widely recognized pro-fibrotic factor orchestrating renal fibrosis is the TGF-b1 cytokine (16, 17) , which was already mice. Data are expressed as the mean 6 s.e.m. Significant differences between WT mice and K.G6pc -/-mice are indicated as *, P < 0.05; **, P < 0.01; *** P < 0.001, respectively. Significant differences between 9 month-and 18 month-K.G6pc -/-mice are indicated as $, P < 0.05 and $$, P < 0.01.
overexpressed in K.G6pc -/-kidneys at 6 months. In line with the development of fibrosis, the expression of Tgfb1 mRNA progressively increased with age in K.G6pc -/-kidneys ( Figure 5B ). As previously shown, the activation of the RAS (illustrated here by the increase in renal angiotensinogen expression) could account for the increase in TGF-b1 expression ( Figure 5A ). Concomitantly with the increase in TGF-b1, epithelial-tomesenchymal transition (EMT) and/or endothelial-tomesenchymal transition (EndoMT) were progressively observed in K.G6pc -/-kidneys over time. The progression of CKD was associated with a 2-fold decrease in the expression of epithelial markers, such as E-Cadherin (Cdh1) and b-catenin (Ctnnb1) ( Figure 5C ). Concomitantly, we observed a progressive increase in the expression of mesenchymal markers, such as vimentin (Vim), fibronectin (Fn1), and collagen type I (Col1a1) ( Figure 5D ). After 18 months, a 10-fold induction of plasminogen activator inhibitor-1 (Pai1) expression was observed in K.G6pc -/-mice compared to WT mice and was significantly higher than after 9
and 15 months of G6pc deletion ( Figure 5D ). In addition to the changes in the EMT markers, we observed a decrease in the amount of two main antioxidant enzymes, catalase and glutathione peroxidase (GPX) after 18 months (Supplementary Material, Fig. S5 ), probably leading to an increase in reactive oxygen species (ROS) accumulation and oxidative stress (18) .
Cystic renal disease and kidney failure in GSD1a patients
Renal status was studied in 32 patients with GSDI (27 with type Ia and 5 with type Ib), in order to detect renal cysts and/or kidney dysfunction (Tables 3 and 4) . Renal failure was defined on the basis of the estimated glomerular filtration rate (eGFR) <60ml/min/1.73 m 2 for more than 3 months. Patients in the cohort were born between 1962 and 2014. The median age of the cohort when the data was collected was 26 years (ranging from 1 to 53 years). The median age of GSDI patients with renal dysfunction was higher than in patients without renal dysfunction (33 and 34 years for groups 2 and 3, respectively versus 22 years for group 1; Table 3 ). Our data suggest that early renal impairment was detected in the young adult GSDI patients (20-30 year-old) (Supplementary Material, Fig. S6 ). The overall prevalence of patients with urinary albumin/creatinine ratio > 20 or of patients treated with renoprotective drugs was 37.5% (13 patients) but only three patients developed renal failure (about 10% of GSDI patients) (Tables 3 and 4 ). Out of the three patients with renal failure, Patient 1 was waiting for renal transplantation and Patient 2 underwent kidney transplantation in 2014. Seven patients (6 with GSDIa and 1 with GSDIb) presented renal cysts, representing 22% of GSDI patients in this cohort (Table 5) and 54% of GSDI patients with renal dysfunction. Interestingly, cysts appeared in GSDI patients at later stages of CKD, characterized by a high albumin/creatinine ratio and a significant decrease of eGFR (Group 3, Table 3 ). Furthermore, all three patients with renal failure (Patients 1 to 3) have developed cysts (Table 4 ; Figure 6 ). Among these 7 patients, one or multiple cysts were detected in both kidneys, mainly in the cortical area ( Table  5 ). The size and number of cysts increased over a 6-8-year follow-up period (Table 5 and Figure 6 ). Most of them were small (size <10mm) but some were supracentimetric (Table 5) . One cyst in Patient 5 was classified as Bosniak II. These results suggest that the development of renal cysts probably appears before kidney failure in patients with GSDI. Despite intensive dietary treatment, hyperlipidaemia was observed in all patients with GSDI, even when patients were treated with lipid-lowering drugs. Indeed, mild and severe (TG > 10g/l) hypertriglyceridemia were observed in GSDI patients with cysts while hypertriglyceridemia was more moderated in GSDI patients without cysts ( Table 3 ). Uric acid levels were similar in all GSDI patients but a majority of them, if not all, were treated with xanthine oxidase inhibitors (Table 3) . However, metabolic parameters could not be associated with the compliance with dietary treatment in this cohort.
Discussion
Until recently, liver damage in GSDI was considered of greater concern than nephropathy. To date, owing to improved nutritional and medical management, GSDI patients have a considerably longer life expectancy and develop renal complications that were not frequently observed before. In this study, a longitudinal study of the progression of CKD in mice with kidneyspecific knockout of G6Pase (K.G6pc -/-mice) allowed us to detect renal cysts before the development of renal failure. Retrospective analyses of the renal status of 32 patients with GSDI showed that renal cysts were detected in seven patients who developed advanced kidney dysfunction. First, we analyzed the progression of CKD in K.G6pc -/-mice that reproduce early-onset GSDIa nephropathy observed in humans (19) . In a previous study, we showed that K.G6pc -/-mice accumulated glycogen in proximal tubules leading to tubular clarification and nephromegaly as well as microalbuminuria after 6 months of G6pc deletion (12) . At this early stage, the first signs of EMT were observed but no fibrosis was detected in the kidneys (12) . Interestingly, we observed almost the same symptoms at 9 months, with increased in albuminuria and polyuria. This indicated the worsening of the nephropathy stage, with considerable tubular dysfunction since the kidneys could no longer concentrate urine successfully. Nevertheless, the glomerular filtration barrier was not damaged at this stage. Between 9 and 18 months, albuminuria increased progressively and the first signs of kidney failure were observed after 15 months of disease. Interestingly, this age corresponded to significant destruction of the glomerular filtration barrier, podocyte depletion, mesangial expansion, tubular fibrosis and inflammation, glomerular sclerosis and to the early development of microscopic cysts. The symptoms worsened at 18 months, with the development of macroscopic cysts. These results suggest that tubular dysfunction leads to the destruction of glomeruli and the filtration barrier, as previously suggested by Lee et al. (20) . The extent to which EMT contributes to renal fibrosis in vivo remains a matter of intense debate (21, 22) . In the context of GSDIa, we observed progressive but partial EMT leading to the development of fibrosis. At the early stages of the nephropathy, we observed a decrease in the expression of epithelial markers. Mesenchymal markers appeared progressively, after 15 months of G6pc deletion. This intermediate stage corresponds with the initiation of chronic inflammation. In addition, glomerular podocytes also undergo transformation after injury, which can lead to podocyte depletion and to defective glomerular filtration and glomerulosclerosis (23, 24) . This process is often accompanied with the fusion of the remaining pedicels in order to decrease filtration damage. In K.G6pc -/-kidneys, podocyte injury and the thickening of the glomerular basement membrane were observed after 15 months, corresponding to kidney failure. Finally, elevated expression of PAI-1 was observed after 15 months, leading to high accumulation of collagen and the development of severe interstitial and glomerular fibrosis (25) . The major driving factors behind EMT during the fibrogenic phase of renal Data were obtained from mouse urine samples collected during 24h using a metabolic cage and are expressed as the mean 6 s.e.m (n ¼ 7-8 mice in each group).
Significant differences between WT and K-G6pc-/-mice are indicated as *P < 0.05; **P < 0.01 and ***P < 0.001. Significant differences between K-G6pc-/-mice over age are indicated as $P < 0.05 and $$P < 0.01. ND: not determined. Data were obtained from mice after 6 h of fasting and are expressed as the mean 6 s.e.m. Significant differences between WT and K-G6pc -/-mice are indicated (*P < 0.05*, **P < 0.01, ***P < 0.001); n ¼ 7-8 mice in each group. fibrosis appear to be various profibrotic growth factors, especially TGF-b1 (17) . The latter was progressively increased during CKD development in K.G6pc -/-mice. We previously suggested that the persistent activation of the RAS is mainly responsible for the induction of TGF-b1 (12) . Nevertheless, there are other mechanisms that might contribute to this profibrotic stimulus, such as activation of the endoplasmic reticulum stress (ER stress) and the subsequent Unfolded Protein Response (UPR), which were shown to activate TGFb1 and promote fibrosis in the kidney (26, 27) . ER stress can be easily triggered by glucose concentration imbalance, as well as metabolite accumulation, both of which being observed in GSD1. Furthermore, apoptosis induced by ER stress alone is sufficient to induce fibrosis. In addition, inflammatory cells epithelial-(C) and mesenchymal-(D) markers by RT-qPCR or Western Blot. The expression of target mRNA in K.G6pc -/-kidneys was expressed relative to WT kidneys at 9, 15 and 18 months. Significant differences between WT mice and K.G6pc -/-mice are indicated as *P < 0.05 and **P < 0.01. Representative Western Blots were shown after 18 months of G6pc deletion. Statistical analyses (student's T test) of Western Blot densitometry analyses showed a 2-fold decrease of E-Cadherin (P ¼ 0.02, n ¼ 4) and b-Catenin (P ¼ 0.001, n ¼ 4) quantity in K.G6pc -/-compared to WT mice. The quantity of Vimentin increased by 2.5-fold (P ¼ 0.01, n ¼ 4) in K.G6pc -/-compared to WT mice.
and cytokines certainly play a vital role in the process of fibroblast activation, as has been demonstrated for diabetic nephropathy (28) . Taken together, these results suggest that EMT and/or EndoMT occur in GSDIa kidneys and play a vital role in the progression of CKD. Finally, the decrease in antioxidant defenses, which is also observed in diabetic kidneys (29) , could participate to the progression of nephropathy in GSDI (30) . Indeed, the production of ROS and oxidative stress are interlinked with TGF-b1 production and thus are key factors in fibrosis (31) . Group 1 corresponds to GSDI patients without renal dysfunction and cysts. Group 2 corresponds to GSDI patients without cyst but with microalbuminuria and/or treated with ACE inhibitors. Group 3 corresponds to GSDI patients with advanced renal impairment and renal cysts. All data were collected in 2015. Creat: creatinine;
Alb: albumin, a: data available from only 4 GSDI patients. Data are expressed as mean 6 s.e.m. Significant differences with Group 1 are indicated as *P < 0.05; ***P < 0.001.
In clinical practice, the most commonly used markers of the progression of renal disease are urinary albumin/creatinine excretion, measurement of serum electrolytes, blood urea and serum creatinine with calculation of eGFR. Unfortunately, not all of them are sufficiently sensitive to detect the early stages of the disease. Urinary LCN2 was recently considered as a promising biomarker of CKD progression, mainly reflecting early defective tubular function (13) (14) (15) . This protein is released from the kidneys in the case of acute kidney injury, long before a decrease in the glomerular rate can be detected (32) . Elevated levels of urinary LCN2 and their inverse correlation with eGFR have also been shown in CKD patients with autosomal dominant polycystic kidney disease (PKD) (33) . In the context of diabetes, conflicting results have failed to confirm urinary LCN2 as a reliable biomarker of CKD progression (32) . Here, the progressive increase in urinary LCN2 levels during the development of kidney disease in K.G6pc
-/-mice probably reflects the deterioration of tubular function. Thus LCN2 could be proposed as a specific biomarker of CKD progression in GSDIa patients. It is noteworthy that recent work has suggested that LCN2 might participate in the pathogenesis of cysts and CKD, by inducing EGFR (Epithelial Growth Factor Receptor) signalling (13) . Interestingly, it might also activate cell proliferation of renal tubules and cysts in other pathological contexts (34) . Consequently, the overexpression of LCN2 in K.G6pc
-/-kidneys could be involved in the progression of the CKD in GSDIa. Finally, GSDIa nephropathy is associated with the activation of a variety of pathways, in particular glycolysis, de novo lipogenesis, and the RAS that leads to the progression of kidney disease (Figure 7 ). The accumulation of glycogen and lipids in the kidneys probably leads to the activation of cell defenses involved in the maintenance of cell homeostasis. Impaired autophagic activity, ER stress and ROS production are involved in the development of CKD (35) . In GSDI, oxidative stress was already shown to mediate nephropathy (30) . Interestingly, recent publications have proposed pharmacological modulation of ER stress for preserving renal function and morphology (15, 36) . In addition, better control of metabolism could be crucial for preventing the progression of renal damage. As suggested for diabetic nephropathy, fat accumulation in K.G6pc -/-kidneys probably causes renal damage due to lipotoxicity and oxidative stress (37, 38) . Moreover, the progression of renal damage has been recently associated with dyslipidemia (39) . In this cohort, hyperlipidaemia tended to be higher in the groups of patients with renal dysfunction (Table 3 , Groups 2 and 3), while more than 50% of these patients were treated with lipidlowering drugs. The synergistic effects of lipid-lowering drugs and blockers of the RAS system in renal protection have been documented in diabetic patients (40) . In addition, the overproduction of uric acid by GSDIa kidneys (due to PPP activation) possibly contributes to the development of CKD. Indeed, uric acid exerts a deleterious effect on renal tubular cells by inducing EMT (41) . The treatment of hyperuricemia with allopurinol was reported to preserve kidney function (7). Thus, a combined therapy including allopurinol, ACE-inhibitors and lipid-lowering drugs has been proposed to slow down CKD in patients with cysts. Despite this combined treatment, three GSDI patients developed renal failure. As CKD appears in young GSDI adults or earlier (8, 9) , a combined therapy from the youngest age could be more efficient, in order to obtain preventive effects rather than curative results. This suggests that care management of GSDI patients should be coordinated by a paediatrician and a nephrologist from the youngest age. It is noteworthy that the ACE-inhibitors significantly delayed the progression of renal damage only in the cases where the therapy was given right when glomerular hyperfiltration was detected (39, 42) . Nephrology recommendations were reported in the clinical practice guidelines of the American College of Medical Genetics and Genomics (6) . In addition to these recommendations, systematic observations of cyst development by kidney imaging should provide a better estimation of the progression of the disease, independently of biochemical markers. Indeed, until recently, abdominal real-time ultrasonography was performed occasionally in order to estimate the enlargement of the kidneys and detect nephrolithiasis or nephrocalcinosis. The quality of the images was not sufficient to precisely detect cysts. More recently, the detection of renal cysts has been facilitated by improved abdominal imaging techniques (higher resolution), such as MRI. Interestingly, imaging of the kidneys has been systematically proposed once a year in patients with GSDI. This allowed us to detect cysts in patients with advanced stage of CKD, before the development of renal failure. Thus renal imaging by MRI should be performed once a year to increase the likelihood of detecting renal cysts in GSDI patients. It is noteworthy that cysts were detected in young adult GSDI patients, as well as in older patients, who all developed severe impairment of kidney function. No cysts were observed in patients with early kidney impairment. Thus, our results suggest that the appearance of cysts is strongly linked to the progression of CKD in GSDI.
In conclusion, the renal pathology of GSDI is characterized by the progressive development of polycystic kidneys, leading to the development of irreversible renal failure in a late stage of the disease. Interestingly, K.G6pc -/-mice developed all of the hallmarks of the nephropathy observed in GSDIa patients. Thus they can be a useful tool in future studies relating to the pharmacological treatment of CKD.
Materials and Methods
Patients
A cohort of 32 patients with GSDI was reviewed retrospectively. All cases of GSDI with mutations were identified at Antoine Beclere Hospital (Clamart), which is the reference centre for rare diseases of hepatic metabolism. Seven patients of this cohort (i.e. 22%) developed renal cysts, which were detected by abdominal real-time ultrasonography and MRI. These examinations are systematically proposed once a year. For this study, the images were retrospectively reviewed on the Picture Archiving and Communication System (PACS), the radiology software, since [2007] [2008] . To count the number of cysts, two radiologists recorded any cyst detected by axial T2-weighted images ( Table 5) .
The clinical and biochemical parameters of these patients, shown in Tables 3 and 4 , were collected in 2015. Urine was collected over 24h. Urinary albumin and protein excretion are expressed as a ratio to creatinine to account for differences in urinary dilution. The eGFR was calculated using the CKI-EPI formula (43) .
Generation of kidney-specific G6pc knock-out mice Deficiency in renal G6Pase was obtained by specific deletion of G6pc exon 3 in the kidney as previously described (12 
Histological analysis
Formalin-fixed and paraffin-embedded kidneys were cut in 4 mm thick sections and stained with hematoxylin and eosin (H&E), or periodic acid Schiff (PAS) staining, or Masson's trichrome staining. Cross-sections (10 mm thick) were obtained from frozen, OCT-embedded tissues and stained with Sudan red. The slides were examined under a Coolscope microscope (Nikon). Section preparations and staining were performed by the "Centre d'histopathologie du petit animal" (Anipath) -University Lyon 1 Laennec, Lyon.
Transmission electron microscopy
A piece of kidney cortex was cut into smaller pieces (1 mm   3 ) and fixed in 2% glutaraldehyde at 4 C. Ultrathin sections (approximately 70 nm thick) were cut on a Reichert ultracut E (Leica) ultramicrotome, mounted on 200 mesh copper grids coated with 1:1,000 polylysine, stabilized for 1 day at room temperature (RT) and contrasted with uranyl acetate and lead citrate by the CIQLE platform (Lyon, Laennec). Sections were examined with a Jeol 1400JEM (Tokyo, Japan) transmission electron microscope equipped with an Orius 1000 camera and Digital Micrograph. Four kidney samples were prepared from each group of mice.
Ten glomerular sections from each mouse were documented and the thickness of the basal membrane was measured and noted at 5 random spots.
Plasma parameters
Blood was withdrawn by submandibular bleeding using a lancet after 6h of fasting and collected in EDTA (0.5M, pH8.0). Plasma triglyceride, cholesterol and uric acid concentrations were determined with Biomé rieux colorimetric kits (Marcy l'Etoile, France). Blood urea nitrogen concentration was measured using a BioAssay Systems colorimetric kit (Hayward, CA, USA).
Urine parameters
Mice were housed in individual metabolic cages (UgoBasile, Comerio, Italy) for 24 h for acclimation before the experiment. Urine was collected for 24 h. Urine urea, creatinine and electrolytes were measured in an automatic analyzer (Konelab, Thermo, France). Albuminuria was assessed using a mouse albumin Elisa kit (Neobiotech) and the uric acid concentration was determined using a colorimetric kit (Biomé rieux, Marcy l'Etoile, France). LCN2 levels were assessed using a mouse Lipocalin-2/NGAL Elisa kit (R&D Systems, Abingdon, UK). Urine pH was determined using strips with DpH ¼ 0.2. Oxalate was measured using gas chromatography mass spectrometry with stable isotope dilution. Citrates were assessed by an enzymatic method using a commercial set (R-Biopharm AG, Darmstadt, Germany).
Gene expression analysis
Western blot analyses were carried out using rabbit polyclonal antibodies against Podocin (Abcam, 1:5,000), Nephrin (Abcam, 1:5,000), E-cadherin (Cell Signalling, 1:1,000), b-catenin (Cell Signalling, 1:1,000), Vimentin (Cell Signalling, 1:1,000), GPX (Abcam, 1:1,000), Catalase (Abcam, 1:2,000), and Histone H3 (Cell Signalling, 1:2,000). Total RNA was isolated according to the Trizol protocol (Invitrogen Life Technologies, Saint Aubin, France). Reverse transcription was done using the Qiagen Quantitec Reverse Transcription kit. Real-time PCRs were performed using sequence-specific primers with SsoAdvanced TM Universal SYBRV R Green Supermix in a CFX Connect TM RealTime System (Bio-Rad). The mouse ribosomal protein ml 19 transcript (Rpl19) was used as reference. Primer sequences are indicated in Supplementary Material, Table S2 .
Statistics
The results are reported as the mean 6 s.e.m. Groups were compared using two-way ANOVA followed by Tukey's post hoc test (against all groups), except for the quantification analyses by Western Blot. An unpaired two-tailed a Student's t test was performed for Western Blot analyses. Differences were considered to be statistically significant at P-value < 0.05.
Study approval
The regional animal care committee (C2EA-55, Université Lyon 1, Lyon) approved all the experiments. Written informed consent was obtained from participants prior to inclusion in the study.
Supplementary Material
Supplementary Material is available at HMG Online.
